Skip to content
Advertisement

FILE - In this Wednesday, April 5, 2017, file photo, Dr. Scott Gottlieb, President Donald Trump's nominee to head the Food and Drug Administration, appears at his confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions, on Capitol Hill in Washington. The Food and Drug Administration is making two moves to rapidly increase the number of generic prescription drugs on sale in an effort to make medicines affordable and prevent future price gouging. New commissioner Gottlieb says the FDA will now give priority reviews to potential generic drugs until at least three are on the market. That’s the level at which prices tend to drop sharply, up to 85 percent off the brand-name price. (AP Photo/J. Scott Applewhite, File)

FILE - In this Wednesday, April 5, 2017, file photo, Dr. Scott Gottlieb, President Donald Trump's nominee to head the Food and Drug Administration, appears at his confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions, on Capitol Hill in Washington. The Food and Drug Administration is making two moves to rapidly increase the number of generic prescription drugs on sale in an effort to make medicines affordable and prevent future price gouging. New commissioner Gottlieb says the FDA will now give priority reviews to potential generic drugs until at least three are on the market. That’s the level at which prices tend to drop sharply, up to 85 percent off the brand-name price. (AP Photo/J. Scott Applewhite, File)

Featured Photo Galleries